Additionally, novel therapeutic agents targeting frequently mutated genes like PIK3CA or BRCA1/2 have been developed and approved for treating patients with human epidermal growth factor 2 (HER2)‐negative breast cancer.11, 12. This evidence concerns the gene PIK3CA and breast carcinoma.